HCPCS Level II code J0175 denotes the 2 mg unit of donanemab-azbt, a monoclonal antibody administered by injection. As a specialty biologic therapy, donanemab-azbt is billed using this HCPCS Level II code when supplied for patient infusion or injection, typically in outpatient infusion centers or hospital outpatient departments. Nationally, precise coding for high-cost specialty drugs like donanemab-azbt matters for accurate claims processing, benefit design, and cost management across public and private payers.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service setting, plus what to expect in payer coverage considerations and common billing practices. The publication summarizes benchmark points, relevant policy developments affecting specialty drug reimbursement, and practical billing and coding considerations tied to HCPCS Level II code J0175. This guide is intended to help billing managers, policy analysts, and revenue cycle staff understand how the code is used and where to look for payer-specific guidance.